Breast Cancer
Balixafortide in combination with eribulin did not improve objective response rate compared to eribulin alone for the treatment of HER2-negative, locally recurrent or metastatic breast cancer, missing the coprimary end point of the FORTRESS study.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
2
Trial Data Show Efficacy, Tolerability of Nivolumab Plus Visogromab in MIBC
3
FDA Grants Orphan Drug Status to Novel CD33-Directed Immunotherapy for AML
4
Talquetamab Combo Yields High Responses in Heavily Pretreated Myeloma
5
